Die Suchmaschine für Unternehmensdaten in Europa

EU-Förderung (1.500.000 €): Dekonstruktion der intestinalen Immuntoleranz Hor 20.09.2023 EU-Rahmenprogramm für Forschung und Innovation "Horizont"

Auf einen Blick

Text

Dekonstruktion der intestinalen Immuntoleranz

The intestinal tract is the main site of nutrient absorption and faces constant exposure to complex environmental stimuli. Intestinal barrier integrity and functionality are safeguarded by the intestinal immune system, which must balance its pro- and anti-inflammatory activities to provide protection from pathogenic microorganisms while preventing unwanted reactivity to self-antigens, commensal microbes, and dietary components. The intestinal immune environment can be viewed as a multicellular network in which the identity and function of individual cells is intrinsically programmed by transcription factors (TFs) that regulate their gene expression. These cells in turn can respond to signals in their environment and impact the behavior of their neighbors, which over time drives changes in tissue physiology. Conventional genetic knockout approaches offer insufficient temporal resolution to dissect these regulatory layers. In this proposal, we will employ chemical genetic protein degradation using the auxin-inducible degron 2 (AID2) system to deconstruct the intestinal immune regulatory network. These studies will focus on the role of Foxp3+ regulatory T (Treg) cells, whose continuous immunosuppressive activity is required to prevent the onset of intestinal inflammation. In Aim 1, we will use newly generated mouse models to probe the direct gene regulatory functions of key TFs that define intestinal Treg cell subsets. In Aim 2, we will fluorescently label intestinal Treg cells and rapidly degrade the TFs that confer their suppressive activity to study their functionality in situ. Finally, in Aim 3, we will use a reversible mosaic protein degradation strategy to study how the signals that precede and promote intestinal Treg cell differentiation shape the developing intestinal immune system. Together, these studies will provide fundamentally new insights into the regulatory network underlying intestinal immune tolerance.


Geförderte Unternehmen:

Firmenname Förderungssumme
Forschungsinstitut FUR Molekulare Pathologie GmbH 1.500.000 €

Quelle: https://cordis.europa.eu/project/id/101116251

Diese Bekanntmachung wurde von Englisch nach Deutsch übersetzt. Die Bekanntmachung bezieht sich auf einen vergangenen Zeitpunkt, und spiegelt nicht notwendigerweise den heutigen Stand wider. Der letzte verfügbare Stand wird auf folgender Seite wiedergegeben: Forschungsinstitut für molekulare Pathologie GmbH, Wien, Österreich.